Immune resilience in response to cancer therapy

Cancer Immunol Immunother. 2020 Nov;69(11):2165-2167. doi: 10.1007/s00262-020-02731-4.

Authors

Joanina K Gicobi¹, Whitney Barham¹, Haidong Dong²

Affiliations

¹ Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN, USA.
² Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN, USA. dong.haidong@mayo.edu.

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / pharmacology*
Antineoplastic Agents, Immunological / therapeutic use
Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors
Costimulatory and Inhibitory T-Cell Receptors / immunology
Humans
Neoplasms / drug therapy*
Neoplasms / immunology
T-Lymphocytes, Cytotoxic / drug effects
T-Lymphocytes, Cytotoxic / immunology
Treatment Outcome
Tumor Escape / drug effects*
Tumor Microenvironment / drug effects
Tumor Microenvironment / immunology*

Substances

Antineoplastic Agents, Immunological
Costimulatory and Inhibitory T-Cell Receptors